UK markets closed
  • FTSE 100

    6,650.78
    -24.69 (-0.37%)
     
  • FTSE 250

    21,304.73
    -131.59 (-0.61%)
     
  • AIM

    1,172.26
    -16.63 (-1.40%)
     
  • GBP/EUR

    1.1614
    +0.0052 (+0.45%)
     
  • GBP/USD

    1.3992
    +0.0039 (+0.28%)
     
  • BTC-GBP

    35,613.43
    -887.83 (-2.43%)
     
  • CMC Crypto 200

    999.68
    +12.47 (+1.26%)
     
  • S&P 500

    3,823.69
    +3.97 (+0.10%)
     
  • DOW

    31,334.53
    +64.44 (+0.21%)
     
  • CRUDE OIL

    64.08
    +2.80 (+4.57%)
     
  • GOLD FUTURES

    1,715.30
    -0.50 (-0.03%)
     
  • NIKKEI 225

    28,930.11
    -628.99 (-2.13%)
     
  • HANG SENG

    29,236.79
    -643.63 (-2.15%)
     
  • DAX

    14,055.29
    -24.74 (-0.18%)
     
  • CAC 40

    5,831.86
    +1.80 (+0.03%)
     

Global Antibiotics Partnering Terms and Agreements Directory 2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy and Technology Target

Research and Markets
·3-min read

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Antibiotics Partnering Terms and Agreements 2010 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Antibiotics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2020 includes:

  • Trends in antibiotics dealmaking in the biopharma industry since 2010

  • Analysis of antibiotics deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life antibiotics deals

  • Access to over 300 antibiotics deal records and contract documents where available

  • The leading antibody deals by value since 2010

  • Most active antibiotics dealmakers since 2010

  • The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy and technology target

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

  • Antibiotics

  • Aminoglycosides

  • Cephalosporin

  • Clindamycin

  • Macrolides

  • Penicillin

  • Quinolones

  • Sulfonamides

  • Tetracycline

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers
4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory
5.1. Introduction
5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

  • Antibiotics

  • Aminoglycosides

  • Cephalosporin

  • Clindamycin

  • Macrolides

  • Metronidazole

  • Penicillin

  • Quinolones

  • Tetracycline

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

For more information about this report visit https://www.researchandmarkets.com/r/2one9s

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900